Trasis Flémalle external view

Ans, May 19, 2026 – Trasis has announced the acquisition of the pharmaceutical production facility formerly operated by Mithra CDMO S.A. (in bankruptcy) in Flémalle, Belgium. This transaction enables Trasis to significantly expand its cleanroom and laboratory production capacities by repurposing high-performance, existing infrastructure.

A state-of-the-art pharmaceutical industrial complex

The “Trasis Flémalle” site will complement the company’s headquarters in Ans, located just 15 minutes away, which will remain its primary hub. By leveraging existing infrastructure, Trasis reduces the environmental footprint, costs, lead times, and risks associated with greenfield real estate developments, while firmly anchoring its regional presence.

The 15-acres site features a 183,000 square feet (17,000 square-meter) GMP pharmaceutical industrial complex built in 2017. It comprises cleanrooms, laboratories, technical facilities, offices, storage space, and a solar farm generating 2 GWh per year. Trasis Flémalle will host additional manufacturing, cleanroom, and laboratory activities. Following a phase of renovation and site adaptation, initial operations are scheduled to begin in early 2027.

Accelerating the strategic plan

Gauthier Philippart, Co-founder and CEO, commented: “This investment in a modern, highly efficient facility expands our production capacity for radiopharmaceutical ingredients. This real estate opportunity allows us to accelerate the first phase of our strategic plan, which was announced in early 2025 with a total investment of approximately €40 million and the creation of 300 jobs by 2030. It solidifies our position as a global leader in synthesis, quality control, and administration equipment for radiopharmaceuticals. Alongside other pioneering Belgian companies, Trasis continues to enhance Belgium’s world-class expertise in nuclear medicine. More broadly, in an evolving geopolitical landscape, we firmly believe that Europe must secure its active pharmaceutical ingredient (API) manufacturing capabilities. We are fully committed to playing our part.”

Real estate strategy realignment

Jean-Luc Morelle, Co-founder and CTO of Trasis, added: “The demand for additional GMP capacity is a direct result of our continuous innovation in patient care. When this opportunity arose, we benchmarked it against an ongoing project on land we had previously acquired near the Ans railway station. We decided to prioritize the ‘Trasis Flémalle’ site due to its immediate availability. Consequently, we are currently exploring alternative opportunities for the 6-hectare ‘Vitalis’ plot—a strategically located site adjacent to the Ans railway station that we had been actively developing over the past two years.”

Contract services for the pharmaceutical industry

Antoine Briffaux, Head of Trasis Ingredients, concluded: “Beyond our core specialization in radiopharmaceuticals, Trasis provides contract services (CDMO) for the broader pharmaceutical industry. This site will foster collaboration with research and biotechnology centers that require development, manufacturing, and packaging services for active ingredients and drug products, including sterile-grade solutions.”

Trasis reaffirms its ongoing commitment to contributing to the global fight against cancer and other life-threatening diseases.

About Trasis

Founded in 2004, the Trasis Group has established itself as a global leader in nuclear medicine, specializing in the design and manufacture of cutting-edge equipment and solutions for the diagnosis and treatment of cancer and neurodegenerative diseases. Every year, nearly 20 million new cancer cases are diagnosed worldwide. In 2025, more than 4.5 million patients benefited from Trasis’ innovative, automated medical technologies, which enhance the quality of care while minimizing side effects. Operating in over 65 countries within hospital nuclear medicine departments, research centers, and radiopharmaceutical companies, Trasis offers integrated solutions spanning the development, production, and administration of radiotracers.

Between 2019 and 2025, Trasis recorded a compound annual growth rate (CAGR) of 33%, significantly outperforming the industry average of 10%, and achieved a turnover of €85 million in 2025. With approximately 470 employees across Belgium, France, the United States, China, and other international regions, over 98% of its production is exported worldwide. Trasis also fosters the biotech and medtech ecosystem by investing in and supporting local startups, contributing to a future where nuclear medicine transforms patient care pathways globally.

Trasis was named the 2025 Ernst & Young “Company of the Year” (Entreprise de l’Année) for French-speaking Belgium.

For more information, please visit: www.trasis.com

Contact media

medias@trasis.com
Laurie Brion, Communication Manager
Jacques Galloy, Board Member

Trasis group acquires pharmaceutical production site in Flémalle